ATE193290T1 - Coa-it- und paf-inhibitoren - Google Patents

Coa-it- und paf-inhibitoren

Info

Publication number: ATE193290T1
Authority: AT; Austria
Prior art keywords: coa; production; arachidonic acid; paf inhibitors; coenzyme
Prior art date: 1992-02-11

Application number

AT93905896T

Other languages

English (en)

Inventor

James David Winkler

Floyd Harold Chilton Iii

Deirdre Mary Bernadette Hickey

Original Assignee

Smithkline Beecham Corp

Smithkline Beecham Plc

Univ Johns Hopkins

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-11

Filing date

1993-02-11

Publication date

2000-06-15

1992-02-11 Priority claimed from GB929202827A external-priority patent/GB9202827D0/en

1993-02-11 Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc, Univ Johns Hopkins filed Critical Smithkline Beecham Corp

2000-06-15 Application granted granted Critical

2000-06-15 Publication of ATE193290T1 publication Critical patent/ATE193290T1/de

Links

239000003848 thrombocyte activating factor antagonist Substances 0.000 title 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 abstract 1
101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 abstract 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
229940114079 arachidonic acid Drugs 0.000 abstract 1
235000021342 arachidonic acid Nutrition 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract 1
239000005516 coenzyme A Substances 0.000 abstract 1
229940093530 coenzyme a Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000010118 platelet activation Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT93905896T 1992-02-11 1993-02-11 Coa-it- und paf-inhibitoren ATE193290T1 (de)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US83388092A	1992-02-11	1992-02-11
US83387992A	1992-02-11	1992-02-11
US83387792A	1992-02-11	1992-02-11
US83385092A	1992-02-11	1992-02-11
US83387892A	1992-02-11	1992-02-11
US83404892A	1992-02-11	1992-02-11
GB929202827A GB9202827D0 (en)	1992-02-11	1992-02-11	Compounds
PCT/US1993/001247 WO1993016674A1 (en)	1992-02-11	1993-02-11	CoA-IT AND PAF INHIBITORS

Publications (1)

Publication Number	Publication Date
ATE193290T1 true ATE193290T1 (de)	2000-06-15

Family

ID=27562876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93905896T ATE193290T1 (de)	1992-02-11	1993-02-11	Coa-it- und paf-inhibitoren

Country Status (13)

Country	Link
US (1)	US5648373A (de)
EP (1)	EP0626969B1 (de)
JP (1)	JP2001527506A (de)
KR (2)	KR100291112B1 (de)
AT (1)	ATE193290T1 (de)
AU (2)	AU3664593A (de)
CA (1)	CA2129897C (de)
DE (1)	DE69328716T2 (de)
DK (1)	DK0626969T3 (de)
ES (1)	ES2149201T3 (de)
GR (1)	GR3034040T3 (de)
PT (1)	PT626969E (de)
WO (1)	WO1993016674A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997004765A1 (en) *	1995-07-25	1997-02-13	Smithkline Beecham Corporation	INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS
US6083949A (en) *	1995-10-06	2000-07-04	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1998007425A1 (en) *	1996-08-21	1998-02-26	Smithkline Beecham Corporation	Imidazole compounds, compositions and use
ES2243016T3 (es) *	1997-12-17	2005-11-16	MERCK & CO., INC.	Antagonistas de receptores de integrinas.
GB9904895D0 (en) *	1999-03-03	1999-04-28	Scarista Limited	Regulators of coenzyme-A-independent transacylase as psychotropic drugs
US20030096854A1 (en) *	2002-06-12	2003-05-22	Ho-Shen Lin	Substituted tricyclics
NZ528405A (en) *	2001-03-26	2005-07-29	Ortho Mcneil Pharm Inc	Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof
EP1506966A3 (de) *	2001-03-26	2005-09-14	Ortho-Mcneil Pharmaceutical, Inc.	Verfahren zur Herstellung von tetrasubstituierte imidazolderivaten sowie deren neue Kristalline Strukturen
FR2823747B1 (fr) *	2001-04-24	2003-05-23	Oreal	Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
FR2823751B1 (fr) *	2001-04-24	2003-05-23	Oreal	Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
MXPA03009850A (es)	2001-04-27	2004-02-12	Bristol Myers Squibb Co	Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
US7091232B2 (en) *	2002-05-21	2006-08-15	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) *	2002-05-21	2008-01-29	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) *	2002-05-21	2008-04-15	Allergan, Inc.	2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
TW200505446A (en) *	2003-01-17	2005-02-16	Fuj Isawa Pharmaceutical Co Ltd	Inhibitor of cox
US20070259875A1 (en) *	2006-04-28	2007-11-08	Atwal Karnail S	Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof
WO2008140251A2 (en) *	2007-05-14	2008-11-20	University-Industry Cooperation Group Of Kyung Hee University	Cyclooxygenase-2 inhibitors
US11970460B1 (en)	2023-10-24	2024-04-30	King Faisal University	4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound
US11999703B1 (en)	2023-10-25	2024-06-04	King Faisal University	5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound
US11939298B1 (en) *	2023-10-25	2024-03-26	King Faisal University	5-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound
US11945783B1 (en)	2023-10-26	2024-04-02	King Faisal University	4-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)butanoic acid as an antimicrobial compound
US11932607B1 (en)	2023-10-27	2024-03-19	King Faisal University	4-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3021338A (en) *	1956-12-05	1962-02-13	Rohm & Haas	Adducts of heterocyclic amides
CH633779A5 (de) *	1977-07-07	1982-12-31	Ciba Geigy Ag	Verfahren zur herstellung neuer vinylaether und deren verwendung zur herstellung von polymeren.
DE2823197A1 (de) *	1978-05-24	1979-11-29	Schering Ag	Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3228271A1 (de) *	1982-07-29	1984-02-02	A. Nattermann & Cie GmbH, 5000 Köln	Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5248689A (en) *	1989-11-06	1993-09-28	Smithkline Beecham Corporation	Substituted N-(imidazolyl)alkyl alanine derivatives
GB9019839D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5087634A (en) *	1990-10-31	1992-02-11	G. D. Searle & Co.	N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5256695A (en) *	1991-07-24	1993-10-26	E. R. Squibb & Sons, Inc.	Acyl amidine and acyl guanidine substituted biphenyl derivatives

1993
- 1993-02-11 ES ES93905896T patent/ES2149201T3/es not_active Expired - Lifetime
- 1993-02-11 CA CA002129897A patent/CA2129897C/en not_active Expired - Fee Related
- 1993-02-11 AT AT93905896T patent/ATE193290T1/de not_active IP Right Cessation
- 1993-02-11 PT PT93905896T patent/PT626969E/pt unknown
- 1993-02-11 KR KR1019940702793A patent/KR100291112B1/ko not_active Expired - Fee Related
- 1993-02-11 EP EP93905896A patent/EP0626969B1/de not_active Expired - Lifetime
- 1993-02-11 DE DE69328716T patent/DE69328716T2/de not_active Expired - Fee Related
- 1993-02-11 AU AU36645/93A patent/AU3664593A/en not_active Abandoned
- 1993-02-11 WO PCT/US1993/001247 patent/WO1993016674A1/en not_active Ceased
- 1993-02-11 JP JP51489693A patent/JP2001527506A/ja not_active Ceased
- 1993-02-11 DK DK93905896T patent/DK0626969T3/da active
- 1993-08-06 US US08/102,877 patent/US5648373A/en not_active Expired - Fee Related
- 1993-11-02 KR KR1020007011694A patent/KR100365913B1/ko not_active Expired - Fee Related
1997
- 1997-10-17 AU AU41867/97A patent/AU701541B2/en not_active Ceased
2000
- 2000-07-27 GR GR20000401730T patent/GR3034040T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2001527506A (ja)	2001-12-25
AU703236B2 (en)	1999-03-18
AU6482698A (en)	1998-07-16
EP0626969A1 (de)	1994-12-07
DE69328716D1 (de)	2000-06-29
GR3034040T3 (en)	2000-11-30
DK0626969T3 (da)	2000-10-30
HK1013421A1 (en)	1999-08-27
KR100291112B1 (ko)	2001-09-17
AU701541B2 (en)	1999-01-28
EP0626969B1 (de)	2000-05-24
PT626969E (pt)	2000-11-30
KR950700734A (ko)	1995-02-20
CA2129897A1 (en)	1993-08-12
AU3664593A (en)	1993-09-13
AU4186797A (en)	1998-01-08
EP0626969A4 (de)	1995-04-19
WO1993016674A1 (en)	1993-09-02
KR100365913B1 (ko)	2002-12-26
DE69328716T2 (de)	2000-11-23
CA2129897C (en)	2006-01-10
ES2149201T3 (es)	2000-11-01
US5648373A (en)	1997-07-15

Legal Events

Date	Code	Title	Description
2001-01-15	UEP	Publication of translation of european patent specification
2006-11-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DK0626969T3 (da)	2000-10-30	CoA-IT- og PAF-inhibitorer
HUP9902103A2 (hu)	1999-10-28	Triarilvegyületek
DE3585981D1 (de)	1992-06-11	Behandlung gewebedegenerativer entzuendungskrankheiten.
DK1119362T3 (da)	2006-06-12	Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion
AU9576901A (en)	2002-04-29	Preparation for the relief of disease
ATE215366T1 (de)	2002-04-15	3-benzoylphenylessigsäure-derivate enthaltende topische zusammensetzungen zur behandlung der ophthalmischen entzündungserkrankungen
DE69531864D1 (de)	2003-11-06	Indolizin spal2 inhibitoren
KR100344712B1 (ko)	2002-12-05	알러지성및염증성질환의치료에유용한화합물
DE69004081D1 (de)	1993-11-25	Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
EP1349562A4 (de)	2008-08-06	Hemmung von gs-fdh zur modulierung der no-bioaktivität
DK1137416T3 (da)	2003-03-03	Anvendelse af langkædede N-alkylderivater af deoxynojirimycin til fremstilling af et lægemiddel til behandling af glycolipidophobnings-sygdomme
ATE284860T1 (de)	2005-01-15	Neue verwendung von phenylheteroalkylamin- derivaten
PT1154993E (pt)	2005-01-31	Derivados de tioamida
DE69920757D1 (de)	2004-11-04	Immunsuppressive wirkungen von pteridinderivaten
ATE231837T1 (de)	2003-02-15	Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
ATE218336T1 (de)	2002-06-15	Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
FI833062A0 (fi)	1983-08-29	Arakidonsyraanaloger som anti-inflammatoriska och antiallergi-medel
DE69935720D1 (de)	2007-05-16	Diamino-propanol-verbindungen zur behandlung von ischaemien
NI200400073A (es)	2005-09-21	Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide
BR0013935A (pt)	2002-05-14	IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
BG108426A (bg)	2005-01-31	Нови производни на сулфоновата киселина
NO983991L (no)	1998-10-30	Serin-protease-inhibitorer
DK0782441T3 (da)	2003-06-30	Farmaceutisk kontrol af inflammation
IT1318667B1 (it)	2003-08-27	Medicamento antinfiammatorio.
IT1263957B (it)	1996-09-05	Impiego terapeutico del pirrolidon carbossilato di piridossina